中文摘要：

目的了解艾滋病病毒感染者／艾滋病患者（HIV／AIDS）接受国家免费抗病毒治疗后的依从性、免疫学变化和生存情况。方法选择闻喜县2004年7月1日至2006年底所有纳入免费抗病毒治疗项目，且年满18周岁的HIV／AIDS纳入研究分析，所有患者在治疗前和治疗后的第0．5、1、2、3、6、9……个月均接受相关流行病学调查和实验室检杏，监测服药依从性、CD4^＋T淋巴细胞计数变化和生存情况等。结果病例平均随访时间为16．5个月[四分位距（IQR）：15．5～20．8个月]。经抗病毒治疗前，病例CD4^＋T淋巴细胞计数中位数值为154个／μl[四分位距（IQR）：81～212个／μl]；治疗后，CD4^＋T淋巴细胞计数均不同程度升高，治疗初3个月增长幅度最大，从基线水平的154个／μl上升到220个／μl（P〈0．001），随后增长减缓，保持在相对稳定水平。相比基线CD4^＋T淋巴细胞计数≥100个／μl的病例，〈100个／μl的病例治疗初3个月该细胞计数增长幅度更大。病例治疗后第3、12、24个月累计生存率分别为0．94、0．88和0．87，应用Cox比例风险回归模型做多因素分析发现，控制初始治疗方案（NVP组和EFV／IDV组）变量后，与基线CD4^＋T淋巴细胞计数〈50个／μl比较，≥50个／μl的病例存活时间更长，死亡危险比（HR）为0．21（95％CI：0．06～0．68）。结论抗病毒治疗对HIV／AIDS具有较好的免疫学治疗效果；患者治疗后生存时间与基线CD4^＋T淋巴细胞计数水平密切相关。

英文摘要：

Objective To assess the adherence,immunologic and survival responses in HIV-infected patients receiving free antiretroviral therapy （ART）. Methods All adult HIV-infected patients in Wenxi county who started antiretroviral treatment （ART） between 01 July 2001 and 31 December 2006 and aged above 18 years were included in this study. Epidemiological survey and laboratory tests were performed before,0.5 months after, 1 months after, 2 months after and every 3 months after initiation of ART to recognize the adherence,efficacy （CD4^＋ T cell counts） and survival to the regimens. Results The median follow-up time period was 16.5 months （Interquartile： 15.5-20.8 months）. At baseline, the median of CD4^＋ T cell counts were 154 cells/μl （Interquartile： 81-212 cells/μl）. Treatment was effective in most of the patients, the CD4^＋ T cell count of patients increased after the initiation of ART. The maximum increase was recorded at month 3, from the median of 154 cells/μl to 220 cells/μl （P〈 0. 001）,and thereafter the count remained stable. When comparing with patients with baseline CD4^＋ T cell count ≥ 100 cells/μl, those with baseline CD4^＋ T cell count 〈 100 cells/μl showed a higher mean increase in the first three months of treatment. The cumulative probability rates of remaining alive were 0.94,0.88 and 0.87 at 3, 12,24 months, respectively. In multivariate Cox＇s proportional hazard models, after adjustment for the type of initial regimens （NVP vs. EFV/IDV）, CD4^＋ T cell count of less than 50 cells/μl （vs. 50 cells/μl or more） was strongly associated with death hazard ratio 0.21（95 % CI：0. 06-0.68）. Conclusion Our data showed that ART was effective for improving immunologic response of adult patients with HIV/AIDS. CD4^＋ T cell count at initiation was associated with survival time in patients starting ART, suggesting that monitoring of CD4^＋ T count should be strengthened to early initiate antiretroviral therapy for HIV-infected patients.